Table 2A.
Association of risk factors with eGFR change over time in the REGARDS study.
| Model 1 | Model 2 | Model 3 | |
|---|---|---|---|
| N=11,997 | N=10,737 | N=10,106 | |
| Beta coefficient (P) | Beta coefficient (P) | Beta coefficient (P) | |
| Age* | −0.13 (<0.001) | −0.11 (<0.001) | −0.08 (<0.001) |
| Male sex | 0.03 (0.33) | −0.009 (0.76) | −0.01 (0.67) |
| Black race | −0.13 (<0.001) | −0.10 (0.002) | 0.02 (0.54) |
| Education ≥ High School | 0.16 (0.007) | 0.11 (0.07) | |
| Household Income ≥ $35,000 | 0.16 (<0.001) | 0.08 (0.01) | |
| Stroke belt | −0.11 (0.001) | −0.10 (<0.001) | |
| Current smoking | −0.05 (0.26) | −0.05 (0.33) | |
| Systolic blood pressure* | −0.10 (<0.001) | ||
| Body mass index* | −0.04 (0.006) | ||
| Diabetes | −0.50 (<0.001) | ||
| Hyperlipidemia | 0.09 (0.006) | ||
| Cardiovascular Disease | −0.06 (0.19) | ||
| Log Urine ACR* | −0.21 (<0.001) |
*
per one standard deviation increase: for age 8 years, for SBP 15 mmHg, for BMI 5.8 kg/m2, for albumin-to-creatinine ratio 0.9 mg/g. Model 3 is additionally adjusted for ACEI/ARB and NSAID use.
Abbreviations: ACEi/ARB—angiotensin converting enzyme inhibitor/angiotensin II receptor blocker; NSAID—non-steroidal anti-inflammatory drug; ACR—albumin-to-creatinine ratio.